Free Trial
NASDAQ:EPIX

ESSA Pharma Q2 2025 Earnings Report

ESSA Pharma logo
$1.68 +0.01 (+0.60%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.67 -0.01 (-0.36%)
As of 05/30/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

ESSA Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ESSA Pharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ESSA Pharma's Q3 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ESSA Pharma Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More ESSA Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ESSA Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ESSA Pharma and other key companies, straight to your email.

About ESSA Pharma

ESSA Pharma (NASDAQ:EPIX), a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

View ESSA Pharma Profile

More Earnings Resources from MarketBeat